- Home
- CLLS vs VFL Comparison
CLLS vs VFL Comparison
Compare CLLS & VFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- VFL
- Stock Information
- Founded
- CLLS 1999
- VFL 1993
- Country
- CLLS France
- VFL United States
- Employees
- CLLS N/A
- VFL N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- VFL Finance/Investors Services
- Sector
- CLLS Health Care
- VFL Finance
- Exchange
- CLLS Nasdaq
- VFL Nasdaq
- Market Cap
- CLLS 148.1M
- VFL 124.0M
- IPO Year
- CLLS 2007
- VFL N/A
- Fundamental
- Price
- CLLS $1.24
- VFL $10.14
- Analyst Decision
- CLLS Buy
- VFL
- Analyst Count
- CLLS 3
- VFL 0
- Target Price
- CLLS $7.00
- VFL N/A
- AVG Volume (30 Days)
- CLLS 836.8K
- VFL 38.0K
- Earning Date
- CLLS 03-13-2025
- VFL 01-01-0001
- Dividend Yield
- CLLS N/A
- VFL 4.16%
- EPS Growth
- CLLS N/A
- VFL N/A
- EPS
- CLLS N/A
- VFL N/A
- Revenue
- CLLS $49,217,000.00
- VFL N/A
- Revenue This Year
- CLLS $1.26
- VFL N/A
- Revenue Next Year
- CLLS N/A
- VFL N/A
- P/E Ratio
- CLLS N/A
- VFL N/A
- Revenue Growth
- CLLS 435.38
- VFL N/A
- 52 Week Low
- CLLS $1.14
- VFL $7.93
- 52 Week High
- CLLS $3.38
- VFL $10.77
- Technical
- Relative Strength Index (RSI)
- CLLS 38.55
- VFL 36.02
- Support Level
- CLLS $1.28
- VFL $10.04
- Resistance Level
- CLLS $1.35
- VFL $10.15
- Average True Range (ATR)
- CLLS 0.07
- VFL 0.08
- MACD
- CLLS 0.01
- VFL -0.02
- Stochastic Oscillator
- CLLS 38.46
- VFL 26.49
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.